Literature DB >> 30878882

Tumor dormancy at bedside: A late awakening.

Romano Demicheli1, Christine Desmedt2, Martine Piccart2, Elia Biganzoli3.   

Abstract

Breast cancer recurrence may occur at variable times following primary tumor removal. The corresponding event dynamics displays a structured multipeak pattern, which can be explained by the occurrence of microscopic phases of metastasis quiescence (tumor dormancy) followed by wake up, growth and timed clinical appearance. This model provides a meaningful justification of the early recurrence pattern and even explains the effectiveness of adjuvant systemic therapies. Yet, late recurrences, which were less investigated, are fairly little known and a few researchers supported their steady state appearance. We report here the analysis of the late clinical course from patients who were disease-free at 5 years of follow-up, which again displays a structured pattern, supporting the view that tumor dormancy can explain the late recurrence risk as well. Tailored treatments are needed to address late clinical recurrences.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Late recurrences; Recurrence dynamics; Tumor dormancy; Tumor homeostasis

Mesh:

Year:  2019        PMID: 30878882     DOI: 10.1016/j.breast.2019.03.001

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  6 in total

1.  Late Recurrence in Breast Cancer: To Run after the Oxen or to Try to Close the Barn?

Authors:  Romano Demicheli; Elia Biganzoli
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

2.  Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Authors:  Romano Demicheli; Christine Desmedt; Mike Retsky; Christos Sotiriou; Martine Piccart; Elia Biganzoli
Journal:  Breast       Date:  2020-05-08       Impact factor: 4.380

Review 3.  The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer.

Authors:  María Inés Diaz Bessone; María José Gattas; Tomás Laporte; Max Tanaka; Marina Simian
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-08       Impact factor: 5.555

Review 4.  The premise of personalized immunotherapy for cancer dormancy.

Authors:  Masoud H Manjili
Journal:  Oncogene       Date:  2020-04-22       Impact factor: 9.867

5.  Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment.

Authors:  Qi Li; Lidong Sun; Li Liu; Qingsen Ran; Xinke Du; Qing Yang; Yajie Wang; Yujie Li; Ying Chen; Xiaogang Weng; Weiyan Cai; Xiaoxin Zhu
Journal:  Front Immunol       Date:  2021-12-28       Impact factor: 7.561

Review 6.  Advances in Breast Cancer Management and Extracellular Vesicle Research, a Bibliometric Analysis.

Authors:  Ramon Handerson Gomes Teles; Rafael Sussumu Yano; Nicolas Jones Villarinho; Ana Sayuri Yamagata; Ruy Gastaldoni Jaeger; Patrick Meybohm; Malgorzata Burek; Vanessa Morais Freitas
Journal:  Curr Oncol       Date:  2021-11-08       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.